NPIL, Lilly Form Another R&D Pact | Chemical & Engineering News
Volume 86 Issue 8 | p. 18 | Concentrates
Issue Date: February 25, 2008

NPIL, Lilly Form Another R&D Pact

Department: Business

Mumbai-based Nicholas Piramal India Ltd. and Eli Lilly & Co. have reached a second drug discovery agreement. NPIL and Lilly will separately conduct early clinical development on different drug candidates directed at the same biological target. NPIL stands to gain as much as $110 million in milestones and royalties if the program is successful. Last year, NPIL licensed a Lilly compound in order to conduct preclinical and clinical studies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment